Department of Molecular and Medical Genetics, School of Medicine, Oregon Health & Science University, Portland, Oregon.
Biostatistics Program, School of Public Health, Oregon Health & Science University, Portland, Oregon.
J Cell Biochem. 2021 Feb;122(2):189-197. doi: 10.1002/jcb.29838. Epub 2020 Aug 12.
The stability and activity of the p53 tumor suppressor protein are tightly regulated by various posttranslational modifications, including SUMOylation. p53 can be modified by both SUMO1 and SUMO2, although how SUMOylation regulates p53 activity is still obscure. Whether p53 activity is directly regulated by deSUMOylation is also unclear. Here, we show that SENP1, a SUMO-specific protease implicated in pro-oncogenic roles, is a p53 deSUMOylating enzyme. SENP1 interacts with p53 and deSUMOylates p53 in cells and in vitro. Knockdown of SENP1 markedly induced p53 transactivation activity. We further show that SENP1 depletion synergizes with DNA damage-inducing agent etoposide to induce p53 activation and the expression of p21, leading to synergistic growth inhibition of cancer cells. Our results reveal that SENP1 is a critical p53 deSUMOylating enzyme and a promising therapeutic target in wild-type p53 containing cancer cells.
p53 肿瘤抑制蛋白的稳定性和活性受到多种翻译后修饰的严格调控,包括 SUMO 化。p53 可以被 SUMO1 和 SUMO2 修饰,尽管 SUMO 化如何调节 p53 活性仍然不清楚。p53 活性是否直接受到去 SUMO 化的调节也不清楚。在这里,我们表明 SENP1,一种与致癌作用相关的 SUMO 特异性蛋白酶,是 p53 的去 SUMO 化酶。SENP1 在细胞内和体外与 p53 相互作用并使 p53 去 SUMO 化。SENP1 的敲低显着诱导了 p53 的转录激活活性。我们进一步表明,SENP1 的耗竭与 DNA 损伤诱导剂依托泊苷协同作用,诱导 p53 激活和 p21 的表达,导致含有野生型 p53 的癌细胞的协同生长抑制。我们的结果表明,SENP1 是 p53 的关键去 SUMO 化酶,是含有野生型 p53 的癌细胞的有前途的治疗靶点。